Part 2: Treating mental illness with psychedelics - A Different Lens

Press/Media: Profile/Interview

Description

A carefully curated team of academics, researchers and scientists are working to revolutionise how we treat mental health issues. Using psychedelics to treat mental illnesses isn’t completely new. While there have been small advances in their applications over the years, there’s still a fundamental lack of understanding of how these drugs work in the brain. World-class researchers across Monash are dedicated to finding out. And they want to investigate the science behind the subjective and therapeutic effects of psychedelics to help create a foundation for safe, new medicines. The Clinical Psychedelic Research Lab, led by Dr Paul Liknaitzky, is spearheading research into the clinical applications of several different psychedelic-assisted treatments for mental health conditions. The Computational and Systems Neuroscience Lab, led by Associate Professor Adeel Razi, is exploring questions of basic science and brain imaging in healthy volunteers. And the Anorexia and Feeding Disorders Group, led by Dr Claire Foldi, is investigating animal models of psilocybin treatment. Coupled with support from the state and federal governments, private partners, industry and global networks, Monash is expertly placed to drive the necessary level of scrutiny on psychedelics and tackle the legacy of a bad reputation from the 1950 and 60s. In Part 2 of this A Different Lens episode, we go inside the clinical trials, discover how researchers will measure changes in the brain and find out why psychedelic-assisted psychotherapy is critical.

Period15 Dec 2021

Media contributions

1

Media contributions

  • TitlePart 2: Treating mental illness with psychedelics - A Different Lens
    Media name/outletYoutube
    Media typeWeb
    Duration/Length/Size10mins 59 secs
    Country/TerritoryAustralia
    Date15/12/21
    DescriptionA carefully curated team of academics, researchers and scientists are working to revolutionise how we treat mental health issues.

    Using psychedelics to treat mental illnesses isn’t completely new. While there have been small advances in their applications over the years, there’s still a fundamental lack of understanding of how these drugs work in the brain.

    World-class researchers across Monash are dedicated to finding out. And they want to investigate the science behind the subjective and therapeutic effects of psychedelics to help create a foundation for safe, new medicines.

    The Clinical Psychedelic Research Lab, led by Dr Paul Liknaitzky, is spearheading research into the clinical applications of several different psychedelic-assisted treatments for mental health conditions. The Computational and Systems Neuroscience Lab, led by Associate Professor Adeel Razi, is exploring questions of basic science and brain imaging in healthy volunteers. And the Anorexia and Feeding Disorders Group, led by Dr Claire Foldi, is investigating animal models of psilocybin treatment.

    Coupled with support from the state and federal governments, private partners, industry and global networks, Monash is expertly placed to drive the necessary level of scrutiny on psychedelics and tackle the legacy of a bad reputation from the 1950 and 60s.

    In Part 2 of this A Different Lens episode, we go inside the clinical trials, discover how researchers will measure changes in the brain and find out why psychedelic-assisted psychotherapy is critical.
    Producer/AuthorMonash University
    URLhttps://www.youtube.com/watch?v=dISqZt0c-YE&t=5s
    PersonsPaul Liknaitzky